Sorrento In-Licenses COVID-19 Targeted MPro Inhibitors

  • Sorrento Therapeutics Inc SRNE has entered into an option agreement with The Texas A&M University System for exclusive rights to highly potent main protease (MPro) inhibitors against SARS-CoV-2. 
  • This latest agreement bolsters Sorrento's portfolio of preclinical and clinical therapeutic candidates targeting COVID-19.
  • Under the agreement terms, Sorrento has an exclusive option to license patents covering the MPro inhibitor drug candidates exclusively.
  • The MPro inhibitors have demonstrated strong cellular antiviral potency against SARS-CoV-2 in preclinical studies. 
  • Several MPro inhibitors were identified that exhibited antiviral effects against diverse SARS-CoV-2 variants. 
  • Sorrento may exercise its right to enter into a worldwide exclusive license agreement at any time during the option period.
  • Price Action: SRNE shares are up 0.32% at $8.96 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!